IN THE NEWS

Mayne Pharma Announces Strategic investment in US Facilities

ABOUT US

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercializing branded and generic pharmaceuticals. Mayne Pharma also provides contract development and manufacturing services to clients worldwide...

Read more

PRODUCTS

To improve patient access to life-enhancing prescription medications, Mayne Pharma offers a robust portfolio of branded and generic drugs in multiple therapeutic areas, including women's health, oncology, dermatology and cardiology.

 

Read more

NEWS AND EVENTS

Mayne Pharma 2021 Annual Report Mayne Pharma appoints new Director Mayne Pharma adds generic Absorica® to US Dermatology portfolio FDA Approves Lexette® for Adolescent Plaque Psoriasis Mayne Pharma 2021 Full Year Media Release

Read more

PARTNERING

One of the keys to Mayne Pharma’s success has been the implementation of strategic partnerships and alliances by licensing products that we are able to market in the USA or Australia and to develop partnerships for the global marketing of products developed by Mayne Pharma...

Read more

SPECIALTY TECHNOLOGIES

Mayne Pharma has a 40-year track record of innovation and success developing new oral drug delivery systems and these technologies have been successfully commercialized in numerous products that continue to be marketed around the world...

Read more

FOR INVESTORS

Last Updated:

ASX:

1.05 AUD
Change: / Open:
Low: High:
Close: Volume:
Market Cap: 52 Week: -

Read more